CJC-1295 (No DAC)

CJC-1295 is a growth-hormone-releasing-hormone analogue developed to extend GHRH activity. Products sold as “CJC-1295 without DAC” are often chemically different from true CJC-1295 and may instead be modified GRF(1-29), making exact sequence verification essential.

GHRH-receptor agonism can stimulate pituitary growth-hormone release and downstream IGF-1 signaling. Duration and pharmacology depend heavily on the exact sequence and presence or absence of a drug-affinity-complex modification.

Limited human research for defined CJC-1295 forms; product-name ambiguity materially weakens evidence transfer.

Level III, Limited human evidence

Research cannot be assigned to a commercial “no DAC” product until sequence, molecular mass, substitutions, and counterion are verified.

FDA has reported serious adverse events associated with CJC-1295 and notes immunogenicity, impurity, and characterization concerns. Endocrine and metabolic effects are plausible.

No FDA-approved drug product; FDA lists significant safety concerns for compounded CJC-1295.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.